Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

PT-141 Bremelanotide 5MG

PT-141

PT-141, also known as Bremelanotide, is a synthetic cyclic peptide derived from the melanocortin peptide family and structurally related to α-melanocyte-stimulating hormone (α-MSH). It is developed and supplied as a research-grade compound for use in laboratory studies focused on central nervous system signaling, melanocortin receptor activity, and peptide–receptor interactions under controlled experimental conditions.*

Unlike compounds that act through vascular or hormonal pathways, PT-141 is primarily studied for its central mechanism of action, targeting melanocortin receptors within the brain. Because of this unique signaling profile, PT-141 is widely referenced in neuroscience, neuroendocrinology, and behavioral research literature as a tool for investigating CNS-mediated physiological responses.*

Key Specifications

  • Peptide Name: PT-141 (Bremelanotide)
  • Peptide Class: Synthetic melanocortin receptor agonist
  • Amino Acid Length: 7 amino acids (cyclic peptide)
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)
— each
— each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

PT-141

Scientific & Research Context

In published scientific literature, PT-141 has been studied for its activity as a melanocortin-3 and melanocortin-4 receptor (MC3R/MC4R) agonist, independent of nitric oxide signaling or peripheral vascular mechanisms.* Research models utilize PT-141 to explore central melanocortin pathways involved in autonomic regulation, motivational signaling, and neuroendocrine communication.*

Within experimental frameworks, PT-141 has been utilized to investigate:*

  • Central melanocortin receptor signaling pathways*
  • CNS-mediated autonomic and neuroendocrine responses*
  • Peptide–receptor binding and structure–activity relationships*
  • Behavioral and motivational signaling models*
  • Comparative studies of melanocortin-derived peptides in vitro*

Its compact cyclic structure, receptor specificity, and well-characterized pharmacological profile make PT-141 a valuable compound for controlled research into peptide-mediated central signaling mechanisms.*

Quality & Analytical Assurance

Each batch of PT-141 is manufactured using validated solid-phase peptide synthesis techniques and subjected to rigorous analytical testing to confirm molecular identity, sequence integrity, and purity. Independent verification by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) ensures batch-to-batch consistency, reliability, and reproducibility for research applications.

Storage & Handling

PT-141 is supplied as a lyophilized powder to maintain stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established laboratory peptide protocols to preserve molecular integrity and minimize degradation.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Hadley, M. E., & Haskell-Luevano, C. “The proopiomelanocortin system.” Annals of the New York Academy of Sciences, vol. 994, pp. 1–11, 2003.
  • Wikberg, J. E. S., et al. “Melanocortin receptors: physiology, pharmacology, and pathophysiology.” Pharmacological Reviews, vol. 52, no. 4, pp. 629–651, 2000.
  • Hruby, V. J., et al. “Design of superpotent cyclic melanotropins based on melanocyte-stimulating hormone.” Journal of Medicinal Chemistry, vol. 38, no. 18, pp. 3454–3461, 1995.
  • Rosen, R. C., et al. “Central nervous system mechanisms of melanocortin action.” Journal of Sexual Medicine, vol. 6, no. 1, pp. 18–26, 2009.
  • Pfaus, J. G., et al. “Melanocortins and sexual behavior.” Neuroscience & Biobehavioral Reviews, vol. 35, no. 9, pp. 1970–1984, 2011.
  • King, S. H., et al. “Bremelanotide activates melanocortin receptors and alters central signaling pathways.” Peptides, vol. 78, pp. 102–109, 2016.
  • Cone, R. D. “Studies on the physiological functions of the melanocortin system.” Endocrine Reviews, vol. 27, no. 7, pp. 736–749, 2006.
  • Wikberg, J. E. S., & Mutulis, F. “Targeting melanocortin receptors: an approach to drug development.” Trends in Pharmacological Sciences, vol. 29, no. 10, pp. 560–566, 2008.
  • Hadley, M. E., et al. “Melanocortin peptides: receptors, functions, and regulation.” Endocrinology, vol. 144, no. 9, pp. 3751–3758, 2003.
  • Giuliani, D., & Catania, A. “Melanocortins in the central nervous system.” Progress in Neurobiology, vol. 76, no. 4, pp. 230–244, 2005.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.